ArticleVaccine2021
Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects.
Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Modeling of antibody waning after heterologous boosting with Ad5-nCoV in individuals primed with two-dose CoronaVac previously.Human vaccines & immunotherapeutics · 2026Trial
- Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial.Emerging microbes & infections · 2023Trial
- Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination.BMC infectious diseases · 2024Article
- Salivary immune responses after COVID-19 vaccination.PloS one · 2024Article
- Magnitude and Durability of the Antibody Response to mRNA-Based Vaccination Among SARS-CoV-2 Seronegative and Seropositive Health Care Personnel.Open forum infectious diseases · 2024Article
- Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers.Journal of medical virology · 2023Article
- Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2- seropositive individuals.The journal of allergy and clinical immunology. Global · 2023Article
- Serological response to COVID-19 pneumonia and increasing severity over 18 months in a prospective cohort of hospitalized patients.Internal and emergency medicine · 2023Article
- Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey.The Journal of infectious diseases · 2023Article
- Smart Immunosensors for Point-of-Care Serological Tests Aimed at Assessing Natural or Vaccine-Induced SARS-CoV-2 Immunity.Sensors (Basel, Switzerland) · 2022Article
- Six months SARS-CoV-2 serology in a cohort of mRNA vaccinated subjects over 90 years old.Scientific reports · 2022Article
- Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccine.Journal of immunological methods · 2022Article
- Article
- Exploratory assessment of serological tests to determine antibody titer against SARS-CoV-2: Appropriateness and limits.Journal of clinical laboratory analysis · 2022Article
- Article
- Article
- Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine.Vaccines · 2021Article
- Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects.Clinica chimica acta; international journal of clinical chemistry · 2021Article
- Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines.Frontiers in medicine · 2021Article
- Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.Frontiers in immunology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe first COVID-19 vaccines are being distributed to the general population. However, the shortage of doses is slowing down the goal of reaching herd immunity. The aim of the study was to verify whether previously SARS-CoV-2 infected subjects, a considerable portion of the population, should receive the same vaccination treatment of seronegative individuals.
methodsHealth-professionals either recovered from COVID-19 or never infected by SARS-CoV-2 were serologically tested at different time-points right before, and several days after, vaccination.
resultsPreviously infected individuals showed humoral immune responses, 21 days after the first dose, that was approximately 10-folds higher than the seronegative group 21 days after the second dose. Seropositivity persists for at least 11 months.
conclusionDuring a shortage of COVID-19 vaccine doses, previously SARS-CoV-2 infected individuals should be dispensed from the vaccination campaign. When dose availability returns to normality, injection of a single dose for seropositive individuals should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.